BlackRock Fund Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock Fund Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$92K	Buy	3,499 +104	+3%	+$3.25K	﹤0.01%	3628
2016 Q3	$137K	Sell	3,395 -5	-0.1%	-$257	﹤0.01%	3559
2016 Q2	$181K	Buy	3,400 +815	+32%	+$45.5K	﹤0.01%	3484
2016 Q1	$154K	Sell	2,585 -192	-7%	-$12.1K	﹤0.01%	3555
2015 Q4	$269K	Buy	2,777 +134	+5%	+$8.91K	﹤0.01%	3421
2015 Q3	$140K	Sell	2,643 -70	-3%	-$4.68K	﹤0.01%	3610
2015 Q2	$216K	Sell	2,713 -18,500	-87%	-$1.58M	﹤0.01%	3498
2015 Q1	$1.57M	Buy	21,213 +1,615	+8%	+$192K	﹤0.01%	3173
2014 Q4	$3.46M	Buy	19,598 +2,918	+17%	+$554K	﹤0.01%	3036
2014 Q3	$3.35M	Buy	16,680 +431	+3%	+$85.5K	﹤0.01%	2970
2014 Q2	$3.52M	Buy	+16,249	New	+$5.41M	﹤0.01%	3017

Other funds holding ATNM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Fund Advisors's ATNM Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Actinium Pharmaceuticals (ATNM) stake by 3.1% in Q4 2016, buying an estimated $3.25K and bringing the position to 3,499 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #3628.

BlackRock Fund Advisors first reported a position in ATNM in Q2 2014 and has held it in 11 quarters since. The position peaked at $3.52M in Q2 2014. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

BlackRock Fund Advisors held 3,499 shares of Actinium Pharmaceuticals worth $92K as of Q4 2016.
BlackRock Fund Advisors bought 104 Actinium Pharmaceuticals shares in Q4 2016, an estimated $3.25K.
Actinium Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3628 holding.
BlackRock Fund Advisors first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Actinium Pharmaceuticals position peaked at $3.52M in Q2 2014.
30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.